Literature DB >> 11966755

Prospects for immune reconstitution in HIV-1 infection.

N Imami1, F Gotch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11966755      PMCID： PMC1906304          DOI： 10.1046/j.1365-2249.2002.01822.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  110 in total

1.  Effects of therapy with highly active anti-retroviral therapy (HAART) and IL-2 on CD4+ and CD8+ lymphocyte apoptosis in HIV+ patients.

Authors:  L Caggiari; S Zanussi; M T Bortolin; M D'andrea; G Nasti; C Simonelli; U Tirelli; P De Paoli
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

2.  Cytotoxic T cells recognize fragments of the influenza nucleoprotein.

Authors:  A R Townsend; F M Gotch; J Davey
Journal:  Cell       Date:  1985-09       Impact factor: 41.582

3.  Assessment of type 1 and type 2 cytokines in HIV type 1-infected individuals: impact of highly active antiretroviral therapy.

Authors:  N Imami; C Antonopoulos; G A Hardy; B Gazzard; F M Gotch
Journal:  AIDS Res Hum Retroviruses       Date:  1999-11-20       Impact factor: 2.205

4.  Therapeutic vaccination (p24-VLP) of patients with advanced HIV-1 infection in the pre-HAART era does not alter CD4 cell decline.

Authors:  D Smith; I Gow; R Colebunders; I Weller; S Tchamouroff; J Weber; F Boag; G Hales; S Adams; G Patou; D A Cooper
Journal:  HIV Med       Date:  2001-10       Impact factor: 3.180

Review 5.  Therapeutic vaccines in HIV.1 infection.

Authors:  F Gotch; G Hardy; N Imami
Journal:  Immunol Rev       Date:  1999-08       Impact factor: 12.988

6.  Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.

Authors:  D L Birx; L D Loomis-Price; N Aronson; J Brundage; C Davis; L Deyton; R Garner; F Gordin; D Henry; W Holloway; T Kerkering; R Luskin-Hawk; J McNeil; N Michael; P Foster Pierce; D Poretz; S Ratto-Kim; P Renzullo; N Ruiz; K Sitz; G Smith; C Tacket; M Thompson; E Tramont; B Yangco; R Yarrish; R R Redfield
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

7.  Low-dose IL-2 reduces lymphocyte apoptosis and increases naive CD4 cells in HIV-1 patients treated with HAART.

Authors:  F Pandolfi; M Pierdominici; M Marziali; M Livia Bernardi; G Antonelli; V Galati; G D'Offizi; F Aiuti
Journal:  Clin Immunol       Date:  2000-03       Impact factor: 3.969

8.  Granulocyte-macrophage colony-stimulating factor augments phagocytosis of Mycobacterium avium complex by human immunodeficiency virus type 1-infected monocytes/macrophages in vitro and in vivo.

Authors:  K Kedzierska; J Mak; A Mijch; I Cooke; M Rainbird; S Roberts; G Paukovics; D Jolley; A Lopez; S M Crowe
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

9.  Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function.

Authors:  H G Fischer; S Frosch; K Reske; A B Reske-Kunz
Journal:  J Immunol       Date:  1988-12-01       Impact factor: 5.422

10.  CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication.

Authors:  C M Walker; D J Moody; D P Stites; J A Levy
Journal:  Science       Date:  1986-12-19       Impact factor: 47.728
View more
  4 in total

Review 1.  What is Good's syndrome? Immunological abnormalities in patients with thymoma.

Authors:  P Kelleher; S A Misbah
Journal:  J Clin Pathol       Date:  2003-01       Impact factor: 3.411

2.  A therapeutic SIV DNA vaccine elicits T-cell immune responses, but no sustained control of viremia in SIVmac239-infected rhesus macaques.

Authors:  Jan zur Megede; Brigitte Sanders-Beer; Peter Silvera; Dawn Golightly; Abigail Bowlsbey; Diane Hebblewaite; Deborah Sites; Lourdes Nieves-Duran; Ranjana Srivastava; Gillis R Otten; Dietmar Rabussay; Lei Zhang; Jeffrey B Ulmer; Susan W Barnett; John J Donnelly
Journal:  AIDS Res Hum Retroviruses       Date:  2008-08       Impact factor: 2.205

3.  Discordant effects of interleukin-2 on viral and immune parameters in human immunodeficiency virus-1-infected monocyte-derived mature dendritic cells.

Authors:  G M Bahr; E C A Darcissac; Y Mouton
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

Review 4.  Host-directed therapies for infectious diseases: current status, recent progress, and future prospects.

Authors:  Alimuddin Zumla; Martin Rao; Robert S Wallis; Stefan H E Kaufmann; Roxana Rustomjee; Peter Mwaba; Cris Vilaplana; Dorothy Yeboah-Manu; Jeremiah Chakaya; Giuseppe Ippolito; Esam Azhar; Michael Hoelscher; Markus Maeurer
Journal:  Lancet Infect Dis       Date:  2016-04       Impact factor: 25.071
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.